These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35288346)

  • 1. Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium.
    Rangarajan HG; Stanek JR; Abdel-Azim H; Modi A; Haight A; McKinney CM; McKeone DJ; Buchbinder DK; Katsanis E; Abusin GA; Ahmed I; Law J; Silva JG; Mallhi KK; Burroughs LM; Shah N; Shaw PJ; Greiner R; Shenoy S; Pulsipher MA; Abu-Arja R
    Transplant Cell Ther; 2022 Jun; 28(6):329.e1-329.e9. PubMed ID: 35288346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders.
    Gupta A; Downey M; Shanley R; Jennissen C; Miller WP; Lund TC; Orchard PJ; Smith AR
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):486-492. PubMed ID: 31751770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
    Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L; Guinan E; Margolis D; Baker KS; Lane A; Boulad F
    Blood; 2017 Apr; 129(16):2308-2315. PubMed ID: 28179273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
    Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Aldenhoven M; Jones SA; Bonney D; Borrill RE; Coussons M; Mercer J; Bierings MB; Versluys B; van Hasselt PM; Wijburg FA; van der Ploeg AT; Wynn RF; Boelens JJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1106-9. PubMed ID: 25708213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
    Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
    Nagler A; Or R; Naparstek E; Varadi G; Slavin S
    Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic cell transplantation for telomere biology diseases: A retrospective single-center cohort study.
    Nichele S; Bonfim C; Junior LGD; Loth G; Kuwahara C; Trennephol J; Funke VAM; Marinho DE; Koliski A; Rodrigues AM; Mousquer RTG; Fasth A; Lima ACM; Calado RT; Pasquini R
    Eur J Haematol; 2023 Sep; 111(3):423-431. PubMed ID: 37259830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.